` EVAX (Evaxion Biotech A/S) vs S&P 500 Comparison - Alpha Spread

EVAX
vs
S&P 500

Over the past 12 months, EVAX has underperformed S&P 500, delivering a return of +4% compared to the S&P 500's +14% growth.

Stocks Performance
EVAX vs S&P 500

Loading
EVAX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EVAX vs S&P 500

Loading
EVAX
S&P 500
Difference
www.alphaspread.com

Performance By Year
EVAX vs S&P 500

Loading
EVAX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Evaxion Biotech A/S vs Peers

S&P 500
EVAX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Evaxion Biotech A/S
Glance View

Market Cap
29.7m USD
Industry
Biotechnology

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

EVAX Intrinsic Value
3.52 USD
Overvaluation 25%
Intrinsic Value
Price
Back to Top